Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2201612 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Can Coronavirus HCoV-229E be Used as a Model Virus Instead of SARS-CoV-2 in Antiviral Efficacy Studies?].
Mikrobiyol Bul
January 2025
Kocaeli Üniversitesi Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Kocaeli.
Son yıllarda pandemi nedeniyle virüslerin tanı ve tedavisine yönelik terapötik yöntemlerin geliştirilmesi ve antivirallerin test edilmesi amacıyla çok sayıda in vitro çalışma yapılmaktadır. Literatürde SARS-CoV-2'nin modellenebilmesi için HCoV-229E'nin kullanımının güvenli ve yeterli olup olmadığını inceleyen çalışmalar sınırlıdır. Bu sebeple bu çalışmada, BSL-2 şartlarında gerçekleştirilebilen HCoV-229E kültürü ve kantitasyon çalışmalarının, BSL-3 şartları gerektiren SARS-CoV-2 deneylerinde bir ön çalışma modeli olup olamayacağının antiviral etkinlik analizleri üzerinden araştırılması amaçlanmıştır.
View Article and Find Full Text PDFBackground: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Danish patients treated with MOV and their clinical outcomes following MOV initiation.
Method: Among all adults (>18 years) who received MOV between 16 December 2021 and 30 April 2022 in an outpatient setting in Denmark, we summarized their demographic and clinical characteristics at baseline and post-MOV outcomes using descriptive statistics.
Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study.
Cent Eur J Public Health
December 2024
Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic.
Objective: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors.
Methods: We conducted a single-centre, descriptive, retrospective study without a comparison group.
Results: Out of 141 patients, 70 (49.
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2.
medRxiv
January 2025
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA.
Molnupiravir is an antiviral medicine that induces lethal copying errors during SARS-CoV-2 RNA replication. Molnupiravir reduced hospitalization in one pivotal trial by 50% and had variable effects on reducing viral RNA levels in three separate trials. We used mathematical models to simulate these trials and closely recapitulated their virologic outcomes.
View Article and Find Full Text PDFSuccessful Sequential Treatment From Remdesivir to Molnupiravir for Prolonged COVID-19 in a Patient With Follicular Lymphoma and Renal Pelvic Carcinoma: A Case Report.
Cureus
December 2024
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JPN.
A 69-year-old Japanese male with follicular lymphoma and renal pelvic carcinoma presented with fever and cough, testing positive for SARS-CoV-2 via PCR. Chest CT revealed ground-glass opacities. Initially, his symptoms improved with a 10-day course of remdesivir (RDV), but they recurred.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!